Table 2. The effect of Cdk5 inhibitor or activator on parameters of DRG excitability.
| Control | 2 min | 4 min | 6 min | 10 min | 15 min | |
| Roscovitine | ||||||
| RMP (mV) | −52±1.3 | −51±1.8 | -47±2.4** | −46±2.1** | −44±2.0** | −43±1.4** |
| FT (mV) | −13.8±0.9 | −12.9±1.1 | −13.4±0.8 | −12.9±2.9 | −13.3±1.6 | −11.9±1.3 |
| Rheobase (pA) | 209±26 | 202±28 | 181±25 | 131±25** | 92±18** | 77±14** |
| Normalized rheobase | 1.0±0 | 0.95±0.03 | 0.86±0.04* | 0.62±0.07** | 0.43±0.05** | 0.36±0.04** |
| RTh (MΩ) | 199±22 | 209±26 | 202±24 | 292±43 | 383±50** | 458±58** |
| Normalized RTh | 1.0±0 | 1.04±0.03 | 1.02±0.05 | 1.49±0.21 | 1.93±0.20** | 2.33±0.25** |
| ß-Amyloid | ||||||
| RMP (mV) | −51±0.5 | −50±2.4 | −50±1.5 | −52±2.8 | −49±1.4 | −49±1.1 |
| FT (mV) | −12.3±1.9 | −13.0±1.4 | −13.1±1.8 | −11.3±1.7 | −11.8±1.8 | −13.4±2.0 |
| Rheobase (pA) | 276±38 | 268±47 | 286±33 | 290±30 | 299±36 | 307±43 |
| Normalized rheobase | 1.0±0 | 0.95±0.04 | 1.08±0.13 | 1.10±0.14 | 1.12±0.12 | 1.15±0.13 |
| RTh (MΩ) | 153±25 | 153±23 | 135±14 | 148±21 | 130±14 | 126±17 |
| Normalized RTh | 1.0±0 | 1.02±0.08 | 0.94±0.11 | 1.01±0.13 | 0.89±0.09 | 0.86±0.11 |
RMP: resting membrane potential; FT: firing threshold; RTh: resistance at threshold. Normalized rheobase: rheobase was normalized to the control. Normalized RTh: RTh was normalized to the control. Data are expressed as mean ± S.E.M. N = 7.
*p<0.05;
**p<0.01. Groups were compared with controls by Anova or Repeated Measures Anova.